Your browser doesn't support javascript.
loading
Successful tandem (autologous-cord blood) SCT in advanced neuroblastomas with highly amplified MYCN.
Goi, K; Inukai, T; Honna, H; Akahane, K; Hirose, K; Kuroda, I; Hasuda, N; Koshizuka, K; Takano, K; Sugita, K.
Afiliación
  • Goi K; Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan. kgoi@yamanashi.ac.jp
Bone Marrow Transplant ; 46(6): 835-9, 2011 Jun.
Article en En | MEDLINE | ID: mdl-20697365
ABSTRACT
Although autologous tandem hematopoietic SCT has improved the prognosis of patients with advanced high-risk neuroblastoma, the results remain unsatisfactory. In an attempt to induce the graft-versus-tumor effect, we performed autologous PBSCT followed by allogeneic cord blood transplantation in three consecutive advanced neuroblastoma cases with marked BM infiltration and high MYCN amplification. Severe acute complications did not occur in any patient and they have maintained disease-free survival for 37-60 months. This strategy appears to be feasible and effective for the treatment of extremely high-risk neuroblastoma cases.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Nucleares / Proteínas Oncogénicas / Trasplante de Células Madre de Sangre del Cordón Umbilical / Trasplante de Células Madre de Sangre Periférica / Neuroblastoma Tipo de estudio: Prognostic_studies Límite: Humans / Infant / Male Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2011 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Nucleares / Proteínas Oncogénicas / Trasplante de Células Madre de Sangre del Cordón Umbilical / Trasplante de Células Madre de Sangre Periférica / Neuroblastoma Tipo de estudio: Prognostic_studies Límite: Humans / Infant / Male Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2011 Tipo del documento: Article País de afiliación: Japón
...